Pernix Therapeutics competitorsClear all

Pernix Therapeutics's top competitors include Alnylam Pharmaceuticals and Celyad.
Pernix Therapeutics
Pernix Therapeutics
Pernix Therapeutics develops and markets branded and generic pharmaceutical products for the pediatric market.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
Celyad
Celyad
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
Founding Date
Founding Date
1997
Founding Date
2002
Founding Date
2007
Type
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Morristown, US HQ
Locations
Cambridge, US HQ
Zug, CH
Windsor And Maidenhead, GB
Locations
Mont-Saint-Guibert, BE HQ
New York, US
Employees
Employees
171
Employees
1,06542% increase
Employees
80
Valuation ($)
Valuation ($)
3 m
Valuation ($)
7.5 b
Valuation ($)
205.7 b
Twitter followers
Twitter followers
308
Twitter followers
11 k
Twitter followers
2.1 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
32
Number of tweets (last 30 days)
13
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
15.4
Average likes per tweet (last 30 days)
4.8
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
374563
Alexa Website Rank
449862
Alexa Website Rank
1093084

Financial

Revenue (est.)
Revenue (est.)
$146.1m (FY, 2017)
Revenue (est.)
$74.9m (FY, 2018)
Revenue (est.)
€3.5m (FY, 2017)
Cost of goods
Cost of goods
$44.6m (FY, 2017)
Cost of goods
$1.8m (FY, 2018)
Cost of goods
€515k (FY, 2017)
Gross profit
Gross profit
$101.4m (FY, 2017)
Gross profit
$73.1m (FY, 2018)
Gross profit
€3m (FY, 2017)
Net income
Net income
($77.1m) (FY, 2017)
Net income
($761.5m) (FY, 2018)
Net income
(€56.4m) (FY, 2017)
For sources of this data, please see the company profile

View company profiles

Alnylam Pharmaceuticals
HQ
Cambridge, US
Employees
1,065↑ 42% increase

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

View company
Celyad
HQ
Mont-Saint-Guibert, BE
Employees
80

Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.

View company